Drug intelligence / Profile preview

phenylarsine oxide

Development stage
Unknown
Modality
Small Molecules
Administration
Laboratory Reagent (not Used As A Clinical Drug), Not Applicable For Human Or Veterinary Drug Administration
01

Overview

Phenylarsine oxide is an organoarsenic small molecule with the formula C6H5AsO, consisting of a phenyl group and an oxygen atom bonded to arsenic[1][2]. It is a cyclic oligomer that in solid form crystallizes as a tetramer. Phenylarsine oxide is notable for its high affinity for vicinal thiol (sulfhydryl) groups in proteins, forming stable cyclic thioarsenite complexes, and is widely used as a biochemical tool for probing thiol-containing proteins and as a membrane-permeable inhibitor of protein tyrosine phosphatases[1][3][5][9][10]. It also acts as a strong oxidant and a prototype trivalent arsenical agent, occasionally used as a surrogate for highly toxic arsenicals (like lewisite) in research settings, and has been used as an antineoplastic agent in some studies[5]. Historically, it has limited use as a poultry coccidiostat in veterinary settings[3]. Phenylarsine oxide exhibits severe biological toxicities, especially via oxidative stress mechanisms, inducing unfolded protein response (UPR) activation and ferroptotic cell death[5][9]. It is a highly toxic compound and is unsuitable for clinical use in humans due to its arsenical toxicity[5][9]. In analytical chemistry, it is used as a reducing agent for determination of chlorine and iodine in wastewater samples[1][7].

Other names
oxophenylarsineoxo(phenyl)arsanephenylarsine oxide mixture of oligomersphenylarsine oxide solutionarsenosobenzenefenylarsinoxidoxophenyl-arsinarsenosobenzen
02

Targets

PPP2CA (Serine/threonine-protein phosphatase PP1-alpha catalytic subunit)

Beyond the preview

Go deeper on phenylarsine oxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phenylarsine oxide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call